Concepedia

Effective inhibition of aromatase inhibitor‐associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole

Nigel Bundred, Ian Campbell, Neville Davidson, R. DeBoer, Holger Eidtmann, Alain Monnier, Patrick Neven, Gϋnter von Minckwitz, J. Miller, Nora Schenk,

Cancer · 2008 · 216 citations · 17 references

DOI

Abstract

At 12 months, immediate zoledronic acid therapy prevented bone loss in postmenopausal women who were receiving adjuvant letrozole.

References

17

Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis

Dennis M. Black, Pierre D. Delmas, Richard Eastell et al. · New England Journal of Medicine · 2007 · 2.9K citations · Full text

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer

Anthony Howell, Jack Cuzick, M Baum et al. · The Lancet · 2005 · 2.3K citations

, , +8

A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer

R. Charles Coombes, Emma Hall, Lorna J. Gibson et al. · New England Journal of Medicine · 2004 · 1.8K citations · Full text

A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer

New England Journal of Medicine · 2005 · 1.6K citations · Full text

Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent Fractures

Ethel S. Siris, Ya-Ting Chen, Thomas A. Abbott et al. · Archives of Internal Medicine · 2004 · 1.1K citations